

# Myocarditis

from the immunological viewpoint

**Anastasios E. Germenis**

*Professor and Head*

agermen@med.uth.gr





Myocarditis is a cardiac disease associated with inflammation of the myocardium and apoptotic degeneration and/or necrosis of adjacent myocytes in the absence of a localized ischemic event

McManus BM.


*Atlas of Cardiovascular Pathology for the Clinician,*  
Philadelphia, 2000

Myocarditis (with or without a DCM phenotype) is an acquired, nongenetic disease of infectious or noninfectious etiology; among the noninfectious causes autoimmunity plays a major role either triggered by a prior infection (e.g., postviral, post-*Trypanosome cruzi*) or without an apparent environmental trigger

Elliott P, et al. *Eur Heart J* 2008; 29:270

# The puzzle of myocarditis

---






# Myocarditis

from the immunological viewpoint


1. Pathogen-induced immune-response-mediated myocardial injury
2. Pathogen-induced anti-cardiac autoimmunity
3. Myocarditis as an organ-specific autoimmune disease

# Immune-mediated myocardial injury in CVB3 myocarditis





# Immune-mediated myocardial injury in *T. cruzi* myocarditis



## Autoreactivity after *T. cruzi* infection

---

Host Component	Host	Molecular Definition
Neurons	H	Serum IgG
Sciatic nerve homogenate	H	Serum IgG
Heart homogenate	H	T cells
Cardiomyocytes	H, Rb	T cells
Heart homogenate	M	T cells
Cardiac myosin	M	CD4+ T cells, serum IgG
43-kDa Muscle glycoprotein	M	Serum IgG
Nervous tissue, heart and skeletal muscle	M	Serum IgG
Second extracellular loop, M2 cholinergic receptor	H,M	Serum IgG
Second extracellular loop, $\beta$ 1 adrenergic receptor	M	Serum IgG
Small nuclear ribonucleoprotein	H	Serum IgG

Marin-Neto JA et al. *Circulation* 2007;115:1109



# Antigenic mimicry

## *Chlamydia*-derived peptides that mimic heart-specific $\alpha$ -mhc-derived peptides

### Immunization

#### Epitope

#### FCA ChTR1

#### M7A $\alpha$

#### kk $\alpha$

#### ChTR1 ChTR1


#### M7A $\alpha$

#### kk $\alpha$

#### M7A $\alpha$ ChTR1

#### M7A $\alpha$

#### kk $\alpha$



Peptide	Amino acid sequence	Prevalence	Severity
M7A $\alpha$	SLKL <b>M</b> ATL <b>F</b> STYASAD	High	High
CHTR1	VLETS <b>M</b> A <b>E</b> FT <b>S</b> TN <b>V</b> IS	High	Mild
CHTR2	VLETS <b>M</b> A <b>E</b> SL <b>S</b> TN <b>V</b> IS	High	Mild
CHTR3	VLETS <b>M</b> A <b>E</b> FI <b>S</b> TN <b>V</b> IS	High	Mild
CHPN	GIEAAV <b>A</b> ESLI <b>T</b> KIVA	High	Mild
CHPS	KIEAAA <b>A</b> ESL <b>A</b> TR <b>F</b> IA	High	Mild
M7A $\beta$	SLKLLSNLFANYASAD	No disease	—

Penninger JM, Bachmaier K. *J Infect Dis* 2000;181(Suppl 3):S498







# Myocarditis

from the immunological viewpoint


1. Pathogen-induced immune-response-mediated myocardial injury
2. Pathogen-induced anti-cardiac autoimmunity
3. Myocarditis as an organ-specific autoimmune disease

## Major Rose-Witebski criteria for autoimmunity fulfilled in myocarditis\_\_\_\_\_

- a. Mononuclear cell infiltration and abnormal HLA expression in the target organ in the absence of infectious agents or known inflammatory causes
- b. Disease induced in animals by immunization with relevant autoantigen, and/or passive transfer of serum, purified autoantibody and/or lymphocytes
- c. Autoantibody and/or autoreactive lymphocytes in situ within the affected tissue
- d. Identification and isolation of autoantigen(s) involved
- e. Circulating autoantibodies and/or autoreactive lymphocytes in patients and in unaffected family members
- f. Efficacy of immunosuppressive therapy



# Histopathological manifestations of myocarditis



- A. Diffuse interstitial myocardial inflammatory infiltrate more prominent around interstitial capillaries and composed of macrophages and lymphocytes.
- B. Vasocentric inflammation (H&E stain).
- C-D. CD68<sup>+</sup> macrophages were the most abundant cells present.
- E. Rare CD3<sup>+</sup> lymphocytes.
- F. Essentially CD20<sup>-</sup> immunohistochemical stain.

Tavora et al. *Diagn Pathol* 2008;3:21



## Major Rose-Witebski criteria for autoimmunity fulfilled in myocarditis\_\_\_\_\_

- a. Mononuclear cell infiltration and abnormal HLA expression in the target organ in the absence of infectious agents or known inflammatory causes
- b. Disease induced in animals by immunization with relevant autoantigen, and/or passive transfer of serum, purified autoantibody and/or lymphocytes**
- c. Autoantibody and/or autoreactive lymphocytes in situ within the affected tissue**
- d. Identification and isolation of autoantigen(s) involved
- e. Circulating autoantibodies and/or autoreactive lymphocytes in patients and in unaffected family members
- f. Efficacy of immunosuppressive therapy







## **Spontaneous myocarditis mimicking human disease occurs in the presence of an appropriate MHC and non-MHC background in transgenic mice**



Taneja V,<sup>\*</sup> Behrens M,<sup>\*</sup> Cooper LT,<sup>‡</sup> Yamada S,<sup>‡</sup> Kita H,<sup>\*</sup> Redfield MM,<sup>‡</sup> Terzic A,<sup>‡</sup> David C<sup>\*</sup>

<sup>\*</sup>*Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA*

<sup>‡</sup>*Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, USA*



**CD4<sup>+</sup> T cells**



**IgG antibodies**

**...against  
cardiac myosin  $\alpha$  heavy chain**






## Major Rose-Witebski criteria for autoimmunity fulfilled in myocarditis\_\_\_\_\_

- a. Mononuclear cell infiltration and abnormal HLA expression in the target organ in the absence of infectious agents or known inflammatory causes
- b. Disease induced in animals by immunization with relevant autoantigen, and/or passive transfer of serum, purified autoantibody and/or lymphocytes
- c. Autoantibody and/or autoreactive lymphocytes in situ within the affected tissue
- d. Identification and isolation of autoantigen(s) involved**
- e. Circulating autoantibodies and/or autoreactive lymphocytes in patients and in unaffected family members
- f. Efficacy of immunosuppressive therapy



# Targets of immune-mediated damage of cardiomyocyte



## Major Rose-Witebski criteria for autoimmunity fulfilled in myocarditis\_\_\_\_\_

- a. Mononuclear cell infiltration and abnormal HLA expression in the target organ in the absence of infectious agents or known inflammatory causes
- b. Disease induced in animals by immunization with relevant autoantigen, and/or passive transfer of serum, purified autoantibody and/or lymphocytes
- c. Autoantibody and/or autoreactive lymphocytes in situ within the affected tissue
- d. Identification and isolation of autoantigen(s) involved
- e. **Circulating autoantibodies and/or autoreactive lymphocytes in patients and in unaffected family members**
- f. Efficacy of immunosuppressive therapy



# Antiheart autoantibodies in myocarditis/DCM

Antibody	Technique	Percentage antibody-positive			
		AM	DCM	OCD	Normals
Muscle-specific					
ASA	s-I IFL	47	10	NT	25
AMLA	AMC	41	9	NT	12
AFA	s-I IFL	28	24	NT	6
IFA	s-I IFL	32	41	NT	3
Heart-reactive					
	s-I IFL	59	20	NT	0
	s-I IFL	NT	12-28	2133	4
Anti-s.Na/K-ATPase	ELISA + western blot	NT	26	NT	2
Organ-specific cardiac	s-I IFL + abs	41	26	1	3
Antimitochondrial					
M7	ELISA	13	31	10	0
ANT	SPRIA	91	57	0	0
BCKD-E2	ELISA	100	60	4	0
Antilaminin	ELISA	73	78	25-35	6
Anti-β1 receptor					
Inhibiting	LBI	NT	30-75	37	18
Inhibiting	ELISA	NT	31	0	12
Stimulating					
	Bioassay	96	95	8	0
	ELISA	NT	26	10	1
	FRET	NT	73	23	0
Anti-M2 receptor	ELISA	NT	39	NT	7.5
Anti-α and β MYHC	Western blot	NT	46	8	0
Anti-MLC 1v	Western blot	NT	35	25	15
Non-myofibrillar					
Anti-MYHC	Western blot	NT	46	17	0
Anti-MLC 1	Western blot	NT	67	42	NT
Antitropomyosin	Western blot	NT	17	0	NT
Antiactin	Western blot	NT	55	21	NT
Anti-HSP-60	Western blot	NT	71	21	NT
Anti-HSP-60, 70	Western blot	NT	85	42	NT
Anti-HSP-60, 70	Western blot	NT	10-14	1-2	3
Anti-β MYHC	ELISA	37	44	16	2.5
Anti-α MYHC	ELISA	17	20	4	2



- **30–40%** of myocarditis/DCM patients and their symptom-free family members
- **1%** of patients with other cardiac disease
- **3%** of normal subjects
- **17%** of patients without cardiac disease, but with autoimmune polyendocrinopathy





AHA predict disease development at 5 years even in the absence of echocardiographic abnormalities (prospective family study) \_\_\_\_\_

## Staging of preclinical DCM


- **No pre-DCM:** negative AHA, normal echocardiogram
- **Early:** positive AHA, normal echocardiogram
- **Advanced:** positivity for one or more AHA
- **Late pre-DCM:** at least one antibody marker, LVE, or dFS

Caforio ALP, et al. *Circulation* 2007; 115:76



# Loci important in autoimmune myocarditis

Li HS, et al. *Autoimmun Rev* 2008; 7:168



# *Thank you for your attention*

---

**Anastasios E. Germenis**

*Professor and Head*

agermen@med.uth.gr

